国际调查:肝素诱导的血小板减少症定义与治疗意见——国际血栓与止血学会科学标准化委员会血小板免疫学小组委员会通讯
国际血栓与止血学会血小板免疫学小组委员会开展国际调查,收集102份意见,了解专家和执业者对直接口服抗凝药在肝素诱导的血小板减少症(HIT)中的应用、HIT样血小板因子4免疫状况新分类定义及静脉免疫球蛋白治疗角色的看法。调查显示,即使血小板未恢复,利伐沙班(74.5%)和阿哌沙班(73.5%)也获广泛接受;静脉免疫球蛋白用于自发性(85.6%)、持续性(83.7%)和治疗难治性HIT(87.4%)的管理也获接受。鉴于这些情况罕见且缺乏高质量证据,小组委员会计划开展更稳健的调查、建立国际共识并起草管理指南。
要点
- 调查显示利伐沙班(74.5%)和阿哌沙班(73.5%)在血小板恢复前即获广泛接受。
- 静脉免疫球蛋白用于自发性(85.6%)、持续性(83.7%)和治疗难治性HIT(87.4%)获接受。
- 小组委员会计划建立国际共识并起草HIT及血小板因子4免疫疾病管理指南。
核心结论
- 调查显示专家和执业者对直接口服抗凝药用于HIT以及静脉免疫球蛋白用于HIT样状况有广泛接受度,小组委员会计划开展更稳健的调查、建立国际共识并起草管理指南。
研究设计与样本
- 国际血栓与止血学会科学标准化委员会血小板免疫学小组委员会开展的国际意见调查,共收到102份回复。
主要发现
- 调查回复中,利伐沙班获74.5%接受,阿哌沙班获73.5%接受,即使在血小板恢复前也获广泛接受。
- 静脉免疫球蛋白用于自发性HIT获85.6%接受,用于持续性HIT获83.7%接受,用于治疗难治性HIT获87.4%接受。
关键数值与推荐
- 利伐沙班接受度74.5%,阿哌沙班接受度73.5%,均包括血小板恢复前使用。
- 静脉免疫球蛋白用于自发性HIT接受度85.6%,持续性HIT 83.7%,治疗难治性HIT 87.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heparin-induced thrombocytopenia (HIT) is rare, affecting fewer than 1 in 1500 hospital admissions. Despite the increasing adoption of new therapies in HIT, such as direct oral anticoagulants and pooled immunoglobulins, there is limited high-quality evidence to guide clinicians. Numerous uncommon presentations of HIT and HIT-like entities have recently been recognized, and a harmonized approach to their classification is required to study them better. We present the results of an international survey of opinions from experts and practitioners in the field of platelet immunology regarding the role of direct oral anticoagulants in HIT, novel definitions of subclassifications of HIT-like platelet factor 4 immune conditions (spontaneous autoimmune HIT, persistent autoimmune HIT, and treatment-refractory HIT), and the role for intravenous immunoglobulins in the treatment paradigm of HIT and these HIT-like conditions. From 102 survey responses, there was broad acceptance of rivaroxaban (74.5%) and apixaban (73.5%) even before platelet recovery, as well as for intravenous immunoglobulin in the management of spontaneous (85.6%), persistent (83.7%), and treatment-refractory HIT (87.4%). With this mandate for harmonizing terminologies and treatment approaches in special situations without robust clinical data owing to their rarity, we plan to conduct a robust survey, establish international consensus, and draft management guidelines for HIT and platelet factor 4 immune diseases in the near future.
引用
- Choi PY, Uzun G, Bakchoul T, et al. Results of an international survey of opinions on the definitions and treatments for heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2024. PMID: 38301999. doi:10.1016/j.jtha.2024.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。